Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TAK and other ETFs, options, and stocks.

About TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. 

CEO
Christophe Weber
CEOChristophe Weber
Employees
47,455
Employees47,455
Headquarters
Osaka, Osaka
HeadquartersOsaka, Osaka
Founded
1781
Founded1781
Employees
47,455
Employees47,455

TAK Key Statistics

Market cap
58.88B
Market cap58.88B
Price-Earnings ratio
74.13
Price-Earnings ratio74.13
Dividend yield
3.25%
Dividend yield3.25%
Average volume
3.18M
Average volume3.18M
High today
$18.49
High today$18.49
Low today
$18.36
Low today$18.36
Open price
$18.40
Open price$18.40
Volume
1.21M
Volume1.21M
52 Week high
$18.49
52 Week high$18.49
52 Week low
$12.99
52 Week low$12.99

TAK News

TipRanks 2h
Takeda Advances Phase 3 Teen Depression Trial, Underscoring Its Neuroscience Strategy

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Takeda (TAK) is running a Phase 3 study called “A Randomized, Double-b...

TipRanks 2h
Takeda Pushes Pediatric Psoriasis Drug TAK-279 Forward With New Phase 3 Trial Update

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Takeda is running a phase 3 trial to test its drug zasocitinib in chil...

TipRanks 2d
Takeda Advances Oral Crohn’s Disease Drug TAK-279 With Active Mid-Stage Trial

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Takeda (TAK) is running a mid-stage study called “A Phase 2b, Multicen...

Analyst ratings

53%

of 15 ratings
Buy
53.3%
Hold
40%
Sell
6.7%

More TAK News

TipRanks 3d
Takeda granted Priority Review for oveporexton by FDA

Takeda (TAK) announced that the FDA accepted its new drug application and granted Priority Review for oveporexton for the treatment of narcolepsy type 1. Ovepor...

TipRanks 3d
Takeda Wins FDA Priority Review for Potential First-in-Class Narcolepsy Drug

Takeda Pharmaceutical Co ( (JP:4502) ) has provided an update. Takeda has had its New Drug Application for oveporexton (TAK-861), an oral orexin receptor 2-sel...

Benzinga 4d
Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery

AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda Pharmaceutical Company Limited (NYSE:TAK) . The...

Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.